Discovery Park Undergraduate Research Internship Program

"CPIP: EGFR Antagonists and Breast Cancer"

About the Project

Project Time & Type:
Full-Year 2010 - CPIP
Research area(s):
Project Description:
We have generated pilot data indicating that the Q43L mutant of the Neuregulin 2beta (NRG2b) peptide growth factor functions as a competitive inhibitor of agonist-induced signaling by the epidermal growth factor receptor (EGFR). Here we propose to use the MDA-MB-231 human breast tumor cell line, which is highly aggressive and exhibits abundant EGFR expression, to evaluate the anti-tumor activity of NRG2b/Q43L. We will overexpress NRG2b/Q43L in the MDA-MB-231 cell line and will evaluate the effects of NRG2b/Q43L on the proliferation, invasiveness, motility, and anchorage-independence of this cell line. Such experiments will explore the anti-tumor activities of NRG2b/Q43L and will provide insights into the utility of ligand-based EGFR antagonists.
Expected Student Contributions:
The intern will learn how to culture MDA-MB-231 human breast tumor cell lines. The intern will learn how to perform studies of tumor cell line proliferation, invasiveness, motility, and anchorage-independence. The intern will learn how to perform fundamental pharmacology analyses. The intern will learn how to record and interpret data, as well as design and troubleshoot experiments.
Related Website(s):
Desired Qualifications:
Estimated Weekly Hours:
Department awards independent research credits for this project?
Yes, 3 credit hours

Professor in Charge

Riese, David
medicinal chem/molecular pharmacology

Student Supervisor

David Riese
Associate Professor

Cooperating Faculty

Julia Kirshner
Biological Sciences
David J. Riese II